uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
Gene Silencing
Advertisement
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Cogent Biosciences Gains FDA Acceptance for Bezuclastinibm
WALTHAM, Mass. and BOULDER, Colo. — September 15, 2026 Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Vertex Partners With Lindsey Vonn to Highlight JOURNAVX
BOSTON — September 15, 2026 Vertex Pharmaceuticals Incorporated announced a partnership with world champion skier Lindsey Vonn to raise...
Arrowhead Advances ARO-DIMER-PA in Mixed Hyperlipidemia
PASADENA, Calif. — September 15, 2026 Arrowhead Pharmaceuticals, Inc. announced interim topline clinical data from the Phase 1/2a ARODIMER-PA-1001...
Advertisements
BridgeBio to Present New Infigratinib Data in Achondroplasia
PALO ALTO, Calif., September 2, 2026 BridgeBio Pharma, Inc. announced plans to present new clinical data on the impact...
uniQure Submits BLA for AMT-130 in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, September 2, 2026 uniQure N.V. announced the submission of a Biologics License Application (BLA) to...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Novartis Del-Brax Shows Breakthrough Potential in FSHD
BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
Advertisement
